A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

662

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic
Leukemia, B-cell
Small Lymphocytic Lymphoma

Interventions

DRUG: Pirtobrutinib
DRUG: Ibrutinib

Sponsor

Loxo Oncology, Inc.